These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 8846041)

  • 1. Microtubule changes in hematologic malignant cells treated with paclitaxel and comparison with vincristine cytotoxicity.
    Hirose Y; Takiguchi T
    Blood Cells Mol Dis; 1995; 21(2):119-30. PubMed ID: 8846041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule organization in lymphoid malignancies.
    Hirose Y; Konda S
    Blood Cells; 1992; 18(2):225-38; discussion 239-40. PubMed ID: 1450424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
    Kurtzberg LS; Roth SD; Bagley RG; Rouleau C; Yao M; Crawford JL; Krumbholz RD; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1029-38. PubMed ID: 19277662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol.
    Rowinsky EK; Donehower RC; Jones RJ; Tucker RW
    Cancer Res; 1988 Jul; 48(14):4093-100. PubMed ID: 2898289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-xL is phosphorylated in malignant cells following microtubule disruption.
    Poruchynsky MS; Wang EE; Rudin CM; Blagosklonny MV; Fojo T
    Cancer Res; 1998 Aug; 58(15):3331-8. PubMed ID: 9699663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrotubular and cytotoxic activity of geiparvarin analogues, alone and in combination with paclitaxel.
    Miglietta A; Bocca C; Gabriel L; Rampa A; Bisi A; Valenti P
    Cell Biochem Funct; 2001 Sep; 19(3):181-9. PubMed ID: 11494307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ; Giannakakou P; Gunasekera SP; Longley RE; Day BW; Hamel E
    Mol Pharmacol; 1997 Oct; 52(4):613-22. PubMed ID: 9380024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death.
    Blagosklonny MV; Giannakakou P; el-Deiry WS; Kingston DG; Higgs PI; Neckers L; Fojo T
    Cancer Res; 1997 Jan; 57(1):130-5. PubMed ID: 8988053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microtubule-damaging agents enhance RASSF1A-induced cell death in lung cancer cell lines.
    Whang YM; Park KH; Jung HY; Jo UH; Kim YH
    Cancer; 2009 Mar; 115(6):1253-66. PubMed ID: 19156899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of drugs affecting microtubular assembly on microtubules, phospholipid synthesis and physiological indices (signalling, growth, motility and phagocytosis) in Tetrahymena pyriformis.
    Kovács P; Csaba G
    Cell Biochem Funct; 2006; 24(5):419-29. PubMed ID: 15912561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implication of bax in apoptosis depends on microtubule network mobility.
    Longuet M; Serduc R; Riva C
    Int J Oncol; 2004 Aug; 25(2):309-17. PubMed ID: 15254727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microtubule-interfering activity of parthenolide.
    Miglietta A; Bozzo F; Gabriel L; Bocca C
    Chem Biol Interact; 2004 Oct; 149(2-3):165-73. PubMed ID: 15501437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis.
    Stewart ZA; Mays D; Pietenpol JA
    Cancer Res; 1999 Aug; 59(15):3831-7. PubMed ID: 10447002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.
    Kamath K; Jordan MA
    Cancer Res; 2003 Sep; 63(18):6026-31. PubMed ID: 14522931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs.
    Carles G; Braguer D; Dumontet C; Bourgarel V; Gonçalves A; Sarrazin M; Rognoni JB; Briand C
    Br J Cancer; 1999 Jun; 80(8):1162-8. PubMed ID: 10376967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts.
    Ong V; Liem NL; Schmid MA; Verrills NM; Papa RA; Marshall GM; Mackenzie KL; Kavallaris M; Lock RB
    J Pharmacol Exp Ther; 2008 Feb; 324(2):434-42. PubMed ID: 17986648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
    Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
    Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunofluorescent studies on cytoplasmic microtubule complex (CMTC) of Vero cells treated with 5,6-diphenylpyridazin-3-one derivatives].
    Liu ZL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1990 Jun; 12(3):213-6. PubMed ID: 1981866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
    Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
    Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.